1. Vasopressors in Septic Shock (A Systematic Review / Meta-Analysis).
- Author
-
Elkady, G. A. M., Elshafei, M. M. N., Mostafa, A. N. S., and Awoad, A. T. A.
- Subjects
- *
SEPTIC shock , *META-analysis , *SEPSIS , *DRUG control , *VASOPRESSIN - Abstract
Background: sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Septic shock occurs in a subset of patients with sepsis and comprises of an underlying circulatory and cellular/metabolic abnormality that is associated with increased mortality. Septic shock is defined by persisting hypotension requiring vasopressors to maintain a mean arterial pressure of 65mm Hg or higher and a serum lactate level greater than 2 mmol/L (18 mg/dL) despite adequate volume resuscitation. Purpose: to assess the role of Vasopressors in septic shock and compare the effects among different types of vasopressor drugs. Patients and Methods: this meta-analysis study was done on 18 studies randomized controlled studies on adult patients (at least 18 years of age) with septic shock and had reported mortality outcome. The study compared five vasopressors EN, DA, VP, TP and PE with norepinephrine (NE) (the control drug) in efficacy and safety. Results: with comparison of the five vasopressors to NE, Vasopressin and its long acting analogue Terlipressin proved to be the competiting agents to NE but not the replacement choices due to many limitations to the study. Conclusion: norepinephrine remains the first choice vasopressor to treat patients with septic shock. The use of vasopressin or terlipressin as a first line vasopressor for the support of MAP is not recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF